FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307804953> ?p ?o ?g. }

• W4307804953 endingPage "A261" @default.
• W4307804953 startingPage "A260" @default.
• W4307804953 abstract "Abstract Background and Aims Portal venous pressure may begin to rise due to steatosis-induced changes in sinusoidal homeostasis in early stages of NASH and may contribute to progression of fibrosis and portal hypertension1. FGF21 is an endogenous hormone regulating carbohydrate, lipid and energy metabolism. FGF21 analogs improve liver and metabolic abnormalities in NASH. In a phase 1b/2a POC study in subjects with NASH, BIO89-100, a glycoPEGylated FGF21 analog, led to significant reductions in hepatic fat fraction (HFF) and liver volume (LV) by MRI-PDFF, with concurrent metabolic benefits and a favorable safety and tolerability profile. This post-hoc analysis assessed the effect of BIO89-100 on spleen volume (SV). Methods The trial enrolled 81 subjects with liver fat ≥10% by MRI-PDFF and biopsy-confirmed NASH or phenotypic NASH. Subjects were treated for 12 weeks in 6 cohorts (3, 9, 18 or 27mg QW; 18 or 36mg Q2W) or placebo. Key endpoints were safety, tolerability, pharmacokinetics, change in HFF by MRI-PDFF and liver and metabolic markers, and have been previously reported. SV was assessed by MRI at baseline, Day 50 and Day 92 in 16 BIO89-100-treated (pooled; 8 on 27 mg QW, 8 on 36 mg Q2W) and 18 placebo subjects. Results Median baseline (BL) characteristics for BIO89-100 subjects (N=16) and placebo subjects (N=18) were: age 47.6 vs 56.5 years, BMI 36.6 vs 33.5 kg/m2, ALT 53 vs. 29 IU/L, VCTE 8 vs 7.1 kPa, liver fat by MRI-PDFF 19.3% vs 19.7%; 56.3% vs 38.9% of subjects were male, and 25% vs 61% had T2DM. Median SV at BL was within normal limits: 232.6 (range 137.6 - 504.4) cm3 vs 170.9 (range 107.6–366.9) cm3. At BL, there were correlations between SV and LV (r=0.58), HOMA-IR (r=0.39), Adipo-IR (r=0.43), BMI (r=0.38) and VCTE score (r=0.40), and negative correlations between SV and HDL cholesterol (r=-0.48), adiponectin (r=-0.35) and platelet count (PC; r=-0.37). On day 92, reduced SV was observed in BIO89-100-treated subjects [percent change LS mean -11.8 vs -0.8 (p=0.002)]. Percent reduction in SV correlated with % reduction in HFF by MRI-PDFF (r=0.55), % reduction in liver fat volume (r=0.55), reduction in HOMA-IR (r=0.55) and % change in CK-18 (r=0.74); and absolute reduction in SV correlated with absolute change in ALT (r=0.48) and negatively correlated with PC (r=-0.75). Conclusion These preliminary data suggest that in non-cirrhotic NASH, a subclinical increase in SV, within the normal range, is associated with a worsening metabolic profile, increased liver stiffness and decreased PC. Normalization of liver fat and LV may be associated with decreased intrahepatic resistance and improved portal flow (PF), thus decreasing SV, and possibly improving insulin sensitivity. The role of SV measurement as a non-invasive tool for assessment of PF and the clinical significance of subclinical changes in SV Presentation: Sunday, June 12, 2022 12:30 p.m. - 2:30 p.m., Monday, June 13, 2022 1:18 p.m. - 1:23 p.m." @default.
• W4307804953 created "2022-11-06" @default.
• W4307804953 creator A5001719819 @default.
• W4307804953 creator A5012311623 @default.
• W4307804953 creator A5054798676 @default.
• W4307804953 creator A5061983367 @default.
• W4307804953 creator A5084413634 @default.
• W4307804953 creator A5085439313 @default.
• W4307804953 creator A5086072427 @default.
• W4307804953 date "2022-11-01" @default.
• W4307804953 modified "2023-09-24" @default.
• W4307804953 title "RF32 | PSUN58 BIO89-100 Treatment Ameliorates a Subclinical Increase in Spleen Volume in Non-cirrhotic NASH in Correlation With Change in Liver Fat, HOMA-IR and Inflammatory Markers in a Phase 1b/2a, Placebo-Controlled, Double-Blind Proof of Concept Study" @default.
• W4307804953 doi "https://doi.org/10.1210/jendso/bvac150.535" @default.
• W4307804953 hasPublicationYear "2022" @default.
• W4307804953 type Work @default.
• W4307804953 citedByCount "0" @default.
• W4307804953 crossrefType "journal-article" @default.
• W4307804953 hasAuthorship W4307804953A5001719819 @default.
• W4307804953 hasAuthorship W4307804953A5012311623 @default.
• W4307804953 hasAuthorship W4307804953A5054798676 @default.
• W4307804953 hasAuthorship W4307804953A5061983367 @default.
• W4307804953 hasAuthorship W4307804953A5084413634 @default.
• W4307804953 hasAuthorship W4307804953A5085439313 @default.
• W4307804953 hasAuthorship W4307804953A5086072427 @default.
• W4307804953 hasBestOaLocation W43078049531 @default.
• W4307804953 hasConcept C106646824 @default.
• W4307804953 hasConcept C126322002 @default.
• W4307804953 hasConcept C134018914 @default.
• W4307804953 hasConcept C142724271 @default.
• W4307804953 hasConcept C170493617 @default.
• W4307804953 hasConcept C197934379 @default.
• W4307804953 hasConcept C204787440 @default.
• W4307804953 hasConcept C27081682 @default.
• W4307804953 hasConcept C2775934546 @default.
• W4307804953 hasConcept C2776175330 @default.
• W4307804953 hasConcept C2777766500 @default.
• W4307804953 hasConcept C2778375690 @default.
• W4307804953 hasConcept C2778772119 @default.
• W4307804953 hasConcept C2779134260 @default.
• W4307804953 hasConcept C2780559512 @default.
• W4307804953 hasConcept C71924100 @default.
• W4307804953 hasConcept C74373430 @default.
• W4307804953 hasConcept C90924648 @default.
• W4307804953 hasConceptScore W4307804953C106646824 @default.
• W4307804953 hasConceptScore W4307804953C126322002 @default.
• W4307804953 hasConceptScore W4307804953C134018914 @default.
• W4307804953 hasConceptScore W4307804953C142724271 @default.
• W4307804953 hasConceptScore W4307804953C170493617 @default.
• W4307804953 hasConceptScore W4307804953C197934379 @default.
• W4307804953 hasConceptScore W4307804953C204787440 @default.
• W4307804953 hasConceptScore W4307804953C27081682 @default.
• W4307804953 hasConceptScore W4307804953C2775934546 @default.
• W4307804953 hasConceptScore W4307804953C2776175330 @default.
• W4307804953 hasConceptScore W4307804953C2777766500 @default.
• W4307804953 hasConceptScore W4307804953C2778375690 @default.
• W4307804953 hasConceptScore W4307804953C2778772119 @default.
• W4307804953 hasConceptScore W4307804953C2779134260 @default.
• W4307804953 hasConceptScore W4307804953C2780559512 @default.
• W4307804953 hasConceptScore W4307804953C71924100 @default.
• W4307804953 hasConceptScore W4307804953C74373430 @default.
• W4307804953 hasConceptScore W4307804953C90924648 @default.
• W4307804953 hasIssue "Supplement_1" @default.
• W4307804953 hasLocation W43078049531 @default.
• W4307804953 hasLocation W43078049532 @default.
• W4307804953 hasOpenAccess W4307804953 @default.
• W4307804953 hasPrimaryLocation W43078049531 @default.
• W4307804953 hasRelatedWork W12296056 @default.
• W4307804953 hasRelatedWork W2036698572 @default.
• W4307804953 hasRelatedWork W2044823377 @default.
• W4307804953 hasRelatedWork W2086939368 @default.
• W4307804953 hasRelatedWork W2113022108 @default.
• W4307804953 hasRelatedWork W2793937758 @default.
• W4307804953 hasRelatedWork W2945890717 @default.
• W4307804953 hasRelatedWork W4207023084 @default.
• W4307804953 hasRelatedWork W4220783228 @default.
• W4307804953 hasRelatedWork W4221000450 @default.
• W4307804953 hasVolume "6" @default.
• W4307804953 isParatext "false" @default.
• W4307804953 isRetracted "false" @default.
• W4307804953 workType "article" @default.